Aclaris Therapeutics IncACRS
Price$5.26Intrinsic value$3.6431% below price

Outlook & Key Dates

Estimates, guidance, catalysts, and upcoming events

Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-14.5%projected annual EPS growth
As of 27 Aug 2026
Analyst Coverage
10analysts covering
Consensus: PositiveAs of 18 Aug 2026
FY EPS (est.)
-$0.66next fiscal year
As of 18 Aug 2026
Monitoring Framework
Key Performance Indicators
Cash Runway Quarterly2K
ATI-052 Half-Life (Days) Annually45.0Target: >= 45
Watch Items
  • ATI-052 Phase 1b Proof-of-Concept Trials in Atopic Dermatitis and AsthmaTrigger: Top-line results releaseAction: Evaluate efficacy signals and safety profiles to support initiation of Phase 2b trials.
  • Bosakitug (ATI-045) Phase 2 Trial in Atopic DermatitisTrigger: Top-line results releaseAction: Assess competitive positioning against existing anti-TSLP therapies.
  • ATI-9494 Investigational New Drug (IND) ApplicationTrigger: IND filing submissionAction: Monitor regulatory clearance to transition the next-generation selective ITK inhibitor into clinical development.
Sign in / Sign up to read more

Research as of 19 Jun 2026

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.